Expecting new data on drug-eluting stents and transcatheter heart valves to feature prominently at Transcatheter Cardiovascular Therapeutics (TCT) 2009 next week in San Francisco, Medtronic, Inc. (NYSE: MDT), today announced plans to showcase its innovative cardiovascular product portfolio, technology pipeline and clinical research at the world’s premier annual meeting for interventional cardiologists.
Three-year results from ENDEAVOR IV>® zotarolimus-eluting coronary stent to Boston Scientific’s Taxus® paclitaxel-eluting coronary stent on the composite safety-and-efficacy endpoint of target vessel failure – will be presented Monday afternoon, at approximately 5:28 pm Pacific time, during The Drug-Eluting Stent Summit Part 1 in Room 104 at San Francisco’s Moscone Center. Principal investigator Dr. Martin B. Leon of New York-Presbyterian Hospital/Columbia University Medical Center and the Cardiovascular Research Foundation will make the presentation.
In addition, three-year results from RESOLUTE>® zotarolimus-eluting coronary stent – will be released on Monday morning, at approximately 8:00 am Pacific time, at the TCT Web site, www.tctconference.com.
TCT 2009 also features a series of posters and presentations on Medtronic’s unique transcatheter valve (TCV) portfolio, which include the Melody® transcatheter pulmonary valve and the CoreValve® and Ventor® transcatheter aortic valves. Medtronic is committed to leading the development of transcatheter valves for all four positions of the heart: aortic, mitral, pulmonic and tricuspid.
The Melody and CoreValve TCVs are approved for use in clinical practice only outside the United States; the Ventor system is an investigational device worldwide. All three TCVs are investigational in the United States. The U.S. clinical study of the CoreValve TCV is expected to start in mid-2010, pending Investigational Device Exemption (IDE) approval by the FDA. The international feasibility study of the Ventor TCV is expected to complete enrollment by the end of 2009.